Abstract:Purpose: Advanced prostate cancer (PCa) has limited treatment regimens and shows low response to chemotherapy and immunotherapy, leading to poor prognosis. Histone modification is a vital mechanism of gene expression and a promising therapy target. In this study, we characterized WD repeat domain 5 (WDR5), a regulator of histone modification, and explored its potential therapeutic value in PCa.Experimental Design: We characterized specific regulators of histone modification, based on TCGA data. The expression and clinical features of WDR5 were analyzed in two dependent cohorts. The functional role of WDR5 was further investigated with siRNA and OICR-9429, a small molecular antagonist of WDR5, in vitro and in vivo. The mechanism of WDR5 was explored by RNA-sequencing and chromatin immunoprecipitation (ChIP).Results: WDR5 was overexpressed in PCa and associated with advanced clinicopathological features, and predicted poor prognosis. Both inhibition of WDR5 by siRNA and OICR-9429 could reduce proliferation, and increase apoptosis and chemosensitivity to cisplatin in vitro and in vivo. Interestingly, targeting WDR5 by siRNA and OICR-9429 could block IFN-γ-induced PD-L1 expression in PCa cells. Mechanistically, we clarified that some cell cycle, anti-apoptosis, DNA repair and immune related genes, including AURKA, CCNB1, E2F1, PLK1, BIRC5, XRCC2 and PD-L1, were directly regulated by WDR5 and OICR-9429 in H3K4me3 and c-Myc dependent manner.Conclusions: These data revealed that targeting WDR5 suppressed proliferation, enhanced apoptosis, chemosensitivity to cisplatin and immunotherapy in PCa. Therefore, our findings provide insight into OICR-9429 is a multi-potency and promising therapy drug, which improves the antitumor effect of cisplatin or immunotherapy in PCa.

Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective

Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think

Identification and Validation of WDR5 WIN-site Ligands Via DNA-encoded Chemical Library Screening

Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5

Screening and Optimization of Phage Display Cyclic Peptides Against the WDR5 WBM Site

Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets

Design, Synthesis, and Initial Evaluation of Affinity-Based Small Molecular Probe for Detection of WDR5.

Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer

Identification of Pyrroloimidazoles As Potential Inhibitors of WDR5-WIN-Site by 3D-QSAR Molecular Simulation

The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2

WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer

Structural Studies of WDR5 in Complex with MBD3C WIN Motif Reveal a Unique Binding Mode

Computational Studies of Novel Aniline Pyrimidine WDR5-MLL1 Inhibitors: QSAR, Molecular Docking, and Molecular Dynamics Simulation

The Role of WDR76 Protein in Human Diseases.

The role of WDR76 in diverse interactions and human diseases

Inhibitors targeting the PWWP domain-containing proteins

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (wdr5)–mixed Lineage Leukemia (MLL) Protein–Protein Interaction

Initial Characterization of WDR5B Reveals a Role in the Proliferation of Retinal Pigment Epithelial Cells

Discovery of DDO-2213 As a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia